Recombinant Human Phosphoinos

Phosphoinositide 3-kinase beta p110b/p85a, PI3Kb, PI3Kb.

The PI3Kb isoform can be activated by insulin via the insulin receptor to initiate a cascade of events that control cell growth and metabolism. The activation of
PI3Kb is mediated by the p85 regulatory subunit binding to tyrosine phosphorylated insulin receptor substrate (IRS) proteins (e.g. IRS-1 and IRS-2).
It was also shown that PI3Kb is involved in apoptosis in human colon carcinoma cells. Injection of neutralizing antibodies specific to p110b in WiDr,
HCT116 and CO 115 adenocarcinoma cells inhibited de novo DNA synthesis.
PI3Kb is the major PI3K isoform required for apoptotic cell and Fc-g receptor mediated phagocytosis shown for primary mouse macrophages and the Jurkat human leukemia T cell line.
It was shown by several research groups that the catalytic subunit of PI3Kb can be activated by Gbg subunits of G-protein coupled receptors.

Phosphoinositide 3-kinase beta Human Recombinant is a glycosilated protein having a molecular weight as follows: p85a chain 83.5 kDa, p110b chain 124.3 kDa.

Sf9 insect cells.

Sterile filtered liquid formualtion.

0.9 mg/ml solution in PBS and 2mM MgCl₂.

Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. 
For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Avoid multiple freeze-thaw cycles.

Greater than 90.0% as determined by SDS Page.

The specific activity was found to be 3,000 units/mg (1 unit is defined as 1 picomole phosphate transferred to PIP2 per minute).

SDS

ProSpec's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.